Welcome to our dedicated page for Codexis news (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis stock.
Codexis, Inc. develops enzyme-based solutions for therapeutics manufacturing, using its CodeEvolver technology to discover and improve high-performance enzymes. Company news commonly covers financial results, guidance, cash-runway commentary, and business updates tied to small molecule pharmaceutical biocatalysis, nucleic acid synthesis, and the ECO Synthesis manufacturing platform for enzymatic RNAi and siRNA production.
Recurring developments include partner and evaluation agreements, technology-transfer activity, quality-system and manufacturing-suite updates, conference data on ECO Synthesis capabilities such as phosphorothioate stereochemistry and ligation efficiency, and portfolio updates for enzymes used in branded pharmaceutical products.
Codexis, a prominent enzyme engineering company, will announce its Q1 2022 financial results on May 5, 2022. The report follows the market's close, and management will host a conference call at 4:30 p.m. ET to discuss results and provide a business update. Investors can access the live webcast on the Codexis Investor Relations website or participate via phone. Codexis leverages its CodeEvolver® platform to create high-performance enzymes for pharmaceuticals and biotherapeutics, aiming to enhance sustainability in manufacturing.
Codexis (CDXS) has announced a strategic partnership with seqWell, leading a $7 million Series C funding round with a $5 million investment. Current investors Research Corporation Technologies and BroadOak Capital Partners also joined the financing. This partnership aims to accelerate seqWell's commercialization of its genomics workflow solutions, notably its plexWell platform, which simplifies NGS library preparation. Codexis will leverage its CodeEvolver technology to enhance seqWell’s products, positioned in the rapidly growing genomics and next-generation sequencing markets.
Codexis (CDXS) and Molecular Assemblies announced advancements in their partnership focused on Fully Enzymatic Synthesis™ (FES™) technology, utilizing Codexis’ engineered enzymes for enhanced DNA synthesis. The collaboration has produced a refined version of terminal deoxynucleotidyl transferase (TdT) polymerase, which improves synthesis accuracy and efficiency. A Key Customer Program will begin later this year, allowing select clients access to long, custom oligonucleotides. FES technology aims to disrupt traditional chemical methods, streamlining synthetic biology applications.
Codexis (Nasdaq:CDXS), an enzyme engineering company, announced participation in the Cowen 42nd Annual Health Care Conference set for March 7-9, 2022. Management will engage in a panel discussion titled “Synthetic Biology Enabling Discovery” on March 8 at 3:30 p.m. ET, followed by a fireside chat on March 9 at 1:30 p.m. ET. Both sessions will be webcasted and accessible in the Investor Relations section of the Codexis website for 30 and 90 days post-event. The company focuses on advancing synthetic biology through innovative enzyme solutions.
Codexis reported a record total revenue of $104.8 million for 2021, marking a 52% increase from 2020 and achieving its eighth consecutive year of revenue growth. Product revenues more than doubled to $70.7 million, driven primarily by sales to Pfizer for the COVID-19 drug PAXLOVID™. The company projects 2022 total revenues between $152 million and $158 million, reflecting anticipated continued growth. Despite increased R&D and SG&A expenses, Codexis maintains a solid cash position of $116.8 million.
Codexis (Nasdaq:CDXS) announced it will report its fourth quarter and fiscal year 2021 financial results on February 24, 2022, after market close. A conference call and webcast for discussing the results will be held at 4:30 p.m. ET. Participants can join the live call by dialing 877-705-2976 (domestic) or (201) 689-8798 (international). The webcast will be available for archiving for 90 days. Codexis leverages its proprietary CodeEvolver platform for novel enzyme development impacting various industries.
Codexis (NASDAQ: CDXS) announced that the FDA has granted orphan drug designation and rare pediatric disease designation for its drug candidate CDX-6512, aimed at treating homocystinuria. This enzyme therapy is in pre-IND development and is positioned as a first-in-class oral treatment. The orphan designation provides incentives such as tax credits and potential marketing exclusivity for seven years upon FDA approval. Preclinical data showcasing CDX-6512 was previously presented at the ICIEM in November 2021.
Codexis, a prominent enzyme engineering company, will participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference, scheduled from January 10-13, 2022. The event will take place virtually, allowing investors and interested parties to access a webcast starting January 10 at 7:00 a.m. ET. This presentation will be archived for 90 days on the company's website. Codexis utilizes its CodeEvolver® platform to enhance enzyme performance across pharmaceuticals, food, and industrial applications, showcasing its commitment to sustainable practices and health improvements.
Codexis, a prominent enzyme engineering company, announced the launch of its Codex® HiTemp Reverse Transcriptase, designed for one-step quantitative reverse transcription PCR (RT-qPCR) applications. This enzyme addresses critical challenges in viral diagnostics, including those for SARS-CoV-2. Key features include enhanced thermostability up to 70°C, improved robustness against clinical sample degradation, and a rapid turnaround time of five minutes for reverse transcription reactions. The enzyme is now available for bulk supply, supporting the ongoing demand for efficient viral RNA detection.
Codexis, Inc. (NASDAQ: CDXS) announced key advancements in biotherapeutic programs targeting homocystinuria (HCU) and maple syrup urine disease (MSUD) at the 14th International Congress of Inborn Errors of Metabolism in Sydney. CDX-6512 demonstrated up to 45% suppression of serum homocysteine in HCU mice, while a leucine decarboxylase showed similar results in MSUD models. Codexis aims to develop these gastrointestinal-stable enzymes as oral therapies, potentially improving treatment options for patients constrained by dietary restrictions. The company remains optimistic about further clinical advancements.